Brief: Aquestive Therapeutics Receives U.S. FDA Approval And Market Access For Libervant Buccal Film In Pediatric Patients Ages 2 To 5
29/04/2024 13:01
April 29 (Reuters) - Aquestive Therapeutics Inc
AQST.O :
* AQUESTIVE THERAPEUTICS RECEIVES U.S. FDA APPROVAL AND
MARKET
ACCESS FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM IN PEDIATRIC
PATIENTS AGES 2 TO 5 AND PROVIDES UPDATE ON ANAPHYLM™
(EPINEPHRINE) SUBLINGUAL FILM
* AQUESTIVE THERAPEUTICS INC: ANAPHYLM PROGRAM ON TRACK; NDA
SUBMISSION EXPECTED BY END OF 2024
* AQUESTIVE THERAPEUTICS INC: ANNOUNCES IMMEDIATE
AVAILABILITY OF
LIBERVANT 5MG, 7.5MG, 10MG, 12.5MG, AND 15MG FOR PATIENTS
BETWEEN 2 TO 5 YEARS OF AGE
Source text for Eikon: ID:nGNX8TyRKX
Further company coverage: AQST.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Inc - Enters Five-Year Term Loan Facility Of Up To $150 Million On May 12, 2026 - SEC Filing
Aquestive Therapeutics Q1 revenue jumps on higher license and royalty income
Brief: Aquestive Therapeutics Announces Completion Of Type A Meeting With FDA For Anaphylm™ (Dibutepinephrine) Sublingual Film
Aquestive misses Q4 revenue estimates, EBITDA loss widens
Brief: Aquestive Therapeutics, Inc. Q4 Net Income USD -31.86 Million